SKI-349

• UNSPSC Description:

  SKI-349 is a dual-targeted inhibitor of sphingosine kinase 1/2 (SPHK1/2) and microtubule assembly (MDA). SKI-349 has anticancer activity. SKI-349 can inhibit the vitality, invasion, and AKT/mTOR signaling pathway of liver cells[1][2].

• Target Antigen:

  Akt; mTOR; SphK

• Type:

  Reference compound

• Related Pathways:

  Immunology/Inflammation;PI3K/Akt/mTOR

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/ski-349.html

• Solubility:

  DMSO : 125 mg/mL (ultrasonic)

• Smiles:

  O=C(C1=C(N)N=C(NC2=CC=C(C=C2)OC)S1)C3=CC=C(C(OC)=C3)OC

• Molecular Weight:

  385.44

• References & Citations:

  [1]Hengst JA, et al. Development of SKI-349, a dual-targeted inhibitor of sphingosine kinase and microtubule polymerization. Bioorg Med Chem Lett. 2020 Oct 15;30(20):127453. |[2]Chen L, et al. SKI-349, a Sphingosine Kinases 1/2 Inhibitor, Suppresses Cell Viability, Invasion, and AKT/mTOR Signaling Pathway, and Shows Synergistic Cytotoxic Effects with Sorafenib in Hepatocellular Carcinoma. Tohoku J Exp Med. 2023 Dec 21.

• Shipping Conditions:

  Room Temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  727686-80-8